Citations

Showing 10 of 108119 citations.

Clinical impact of loss of H3K36me3 expression in patients with clear cell renal cell carcinoma.
Swaika, Abhisek, Serie, Daniel, Eckel‐Passow, Jeanette E. , Parker, Alexander S. , Ho, Thai H. , Kapur, Payal , Brugarolas, James , Joseph, Richard W.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4563-4563

10.1200/jco.2015.33.15_suppl.4563 Get It

Molecular analysis of sarcomatoid renal cell carcinoma (sRCC).
Millis, Sherri Z. , Bryant, David , Gatalica, Zoran , Stanton, Melissa, Castle, Erik P., Ho, Thai H. , Reddy, Sandeep K. , Joseph, Richard W. , Vogelzang, Nicholas J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4556-4556

10.1200/jco.2015.33.15_suppl.4556 Get It

Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Barrios, Pablo M. , Albigès, Laurence , Krajewski, Katherine M. , Pal, Sumanta K. , Heng, Daniel Yick Chin, Kwiatkowski, David J. , Thorner, Aaron R. , Rini, Brian I. , Agarwal, Neeraj , Ho, Thai H. , Van Allen, Eliezer M , Porta, Camillo , Bellmunt, Joaquim , McDermott, David F. , Signoretti, Sabina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4519-4519

10.1200/jco.2015.33.15_suppl.4519 Get It

Prognostic impact of peripheral blood counts in patients with non-metastatic clear cell renal cell carcinoma.
Hammond, William A. , Hassan, Lauren, Serie, Daniel, Eckel‐Passow, Jeanette E. , Leibovich, Bradley C. , Thompson, R. Houston, Cheville, John C. , Parker, Alexander S. , Hammond, William Adam, Lewis, Daniel, Ho, Thai H. , Joseph, Richard W.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15590-e15590

10.1200/jco.2015.33.15_suppl.e15590 Get It

Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.
Pavel, Marianne, Lam, Du, Kunz, Tiffany, Brandt, Ulrike , Capdevila, Jaume , Tomassetti, Paola, Hobday, Timothy J. , Pommier, Rodney F. , Lombard‐Bohas, Catherine , Cutsem, Eric Van , Vries, Elisabeth G.E. de , Yao, James C.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4091-4091

10.1200/jco.2015.33.15_suppl.4091 Get It

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
Ahmad, Syed A. , Marsh, Robert , Collisson, Eric A. , Schwartz, Lawrence H., Martin, Robert C.G. , Conway, William, Truty, Mark J. , Kindler, Hedy L. , Lowy, Andrew M. , Philip, Philip Agop, Cardin, Dana B. , LoConte, Noelle K. , Cardin, Dana B , LoConte, Noelle , Katz, Matthew H. G. , Shi, Qian , Herman, Joseph M. , Bekaii‐Saab, Tanios , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4008-4008

10.1200/jco.2015.33.15_suppl.4008 Get It

Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. , Fruth, Briant, Kunz, Pamela L. , Kennecke, Hagen F. , Wolin, Edward M. , Niedzwiecki, Donna , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2015.33.15_suppl.4005 Get It

Body mass index and mortality in patients with pancreatic cancer: A systematic review and meta-analysis of observational studies.
Arora, Nivedita , Sen, Shiraj, Naina, Harris, Singh, Siddharth , Gupta, Arjun , Majumder, Kaustav, Singh, Preet Paul

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15293-e15293

10.1200/jco.2015.33.15_suppl.e15293 Get It

A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Ko, Andrew H. , Chiorean, E. Gabriela , Kwak, Eunice L., Lenz, Heinz‐Josef , Nadler, Paul I., Wood, Debra L., Fujimori, Masamoto, Morita, Kohei , Inada, Tetsuhi, Kouji, Hiroyuki , McWilliams, Robert R. , Fujimori, Masamoto

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15270-e15270

10.1200/jco.2015.33.15_suppl.e15270 Get It

Time-dependent patterns of recurrence and death in resected colon cancer (CC): Pooled analysis of 12,223 patients from modern trials in the ACCENT database containing oxaliplatin.
Renfro, Lindsay A. , Allegra, Carmen J. , Gramont, Aimery de , Haller, Daniel G. , Shah, Manish A , André, Thierry , Sinicrope, Frank A. , Schmoll, Hans‐Joachim , Alberts, Steven R. , Yothers, Greg , Sargent, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3593-3593

10.1200/jco.2015.33.15_suppl.3593 Get It